PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Following the failure of its core drug pipeline and a change of controlling shareholder, Parataxis Korea has pivoted to a bitcoin treasury business, and is now navigating a highly unusual situation involving a delisting process, a pending court injunction, and a merger timeline with an affiliate—all at once.
KRX's Corporate Examination Committee (July 1) and the KOSDAQ Market Committee (August 19) both resolved to delist the stock, and the company's formal objection was not accepted.
On August 20 the company filed for an injunction to stay the delisting decision and cleanup-trading process at the Seoul Southern District Court, and the procedures remain suspended pending the court's ruling.
The Phase 2 failure of its core drug candidate BBT-877 was the direct trigger for financial deterioration and the change of controlling shareholder, after which the business was reorganized around a bitcoin treasury platform.
Annual revenue has been limited to only a few million to tens of millions of won, while operating losses have persisted at roughly 15 billion to 44 billion won every year, with operating cash flow negative in all four years.
The absorption-merger schedule with affiliate Parataxis Ethereum (general meeting, merger date, new-share listing) has been pushed back by three to four months each, intertwined with the delisting process.
Parataxis Korea began as Bridge Biotherapeutics, a drug developer working on treatments for inflammatory bowel disease, idiopathic pulmonary fibrosis (IPF), and non-small cell lung cancer.
Its core pipeline asset, the IPF candidate BBT-877, failed to meet its primary endpoint in a global Phase 2 trial, and this failure was the direct trigger for a change of controlling shareholder and a subsequent business overhaul.
In June 2025, Parataxis Korea Fund I, affiliated with a cryptocurrency hedge fund manager, acquired control through a 20 billion won third-party share placement and a 5 billion won convertible bond issuance, and the company was renamed Parataxis Korea that August.
The company subsequently pivoted away from its legacy biotech pipeline toward a bitcoin treasury platform business as its new focus. According to available data, the company holds roughly 200 BTC, placing it among the higher-ranked corporate bitcoin holders in Korea.
In April 2026 its board decided on an absorption merger with affiliate Parataxis Ethereum, under which Parataxis Ethereum would survive and Parataxis Korea would be dissolved, as part of an ongoing governance restructuring.
However, because Parataxis Korea was designated a managed issue and simultaneously underwent listing-eligibility review, the merger schedule itself has been revised multiple times.
As a result, the company's current business identity sits somewhere between a legacy pharmaceutical company and an emerging digital-asset treasury company.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩0 | -₩4.7B | — |
| 2025Q3 | ₩0 | -₩3.4B | — |
| 2025Q4 | ₩0 | -₩2.1B | — |
| 2026Q1 | ₩300M | -₩2.1B | −642.7% |
| 2026Q2 | ₩1.3B | -₩2.3B | −179.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩3B | -₩43.5B | -₩41.7B | −1438.7% | −80.4% | 18.5% |
| 2023 | ₩100M | -₩40.3B | -₩42.5B | −40349.3% | −220.0% | 65.7% |
| 2024 | ₩2,178,072 | -₩19B | -₩19.9B | −872715.1% | −75.9% | 21.5% |
| 2025 | ₩9,000,000 | -₩15.2B | -₩32.2B | −168375.6% | −73.7% | 61.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue in 2025 was just 9 million won, while the operating loss reached 15.154 billion won and the net loss attributable to owners was 32.240 billion won.
In 2024, revenue was even smaller at roughly 2.18 million won, yet the operating loss of 19.008 billion won and net loss of 19.933 billion won were comparable to or larger than 2025 on several line items.
Operating losses in 2023 and 2022 were 40.349 billion won and 43.501 billion won respectively—the largest of the four years—with net losses of similar magnitude at 42.455 billion won and 41.700 billion won.
In other words, annual operating losses narrowed from the 40-billion-won range in 2022-2023 to the 15-19-billion-won range in 2024-2025, but revenue remains too small to offset losses, so a loss-absorbing business base has yet to form.
On a quarterly basis, the net loss attributable to owners widened sharply to 19.229 billion won in Q4 2025 from -3.497 billion won in the prior quarter and -4.588 billion won two quarters earlier; because this widening far exceeded the increase in the operating loss (-2.084 billion won), it suggests a one-off item likely affected non-operating results.
By contrast, Q1 and Q2 2026 saw revenue of 319 million won and 1.274 billion won respectively—the first meaningful revenue in the last five quarters—likely reflecting the newly adopted business following the pivot.
Even so, operating losses of 2.052 billion won and 2.280 billion won in those quarters far exceeded revenue, meaning the new business has not yet contributed to earnings improvement. The net loss attributable to owners summed over the trailing four quarters (Q3 2025 through Q2 2026) totals 30.907 billion won.
Equity fell from 51.865 billion won in 2022 to 19.720 billion won in 2023, then rebuilt to 43.790 billion won by the end of 2025 through large capital raises in 2024-2025; over this period the debt ratio rose from 21.5% in 2024 to 61.8% in 2025, and operating cash flow was negative in all four years (-14.580 billion won in 2025), indicating that cash-generating capability from core operations has yet to be established.
The industry Parataxis Korea originally belonged to is the market for inflammatory bowel disease and idiopathic pulmonary fibrosis treatments; in ulcerative colitis, anti-TNF agents such as infliximab, adalimumab, and golimumab are already established as standard care, with randomized controlled trials confirming clinical and endoscopic remission benefits over placebo.
More recently, biologics with different mechanisms such as ustekinumab (Stelara) have also become part of domestic clinical practice, making the competitive landscape fairly intense.
Against this backdrop, the company's core pipeline asset BBT-877 failed to deliver results in a global Phase 2 trial for IPF, costing it momentum for licensing deals or further development.
The bitcoin treasury business the company subsequently pivoted to remains an early-stage, emerging area even domestically; other KOSDAQ- and KOSPI-listed companies such as Wemade (223 BTC), Bitplanet (300 BTC), and Bitmax (551 BTC) reportedly hold bitcoin in similar fashion.
However, this sector still lacks fully standardized accounting and disclosure practices or a settled regulatory framework, and how fluctuations in the value of digital assets held by companies affect reported earnings has not been institutionally well tested.
In Parataxis Korea's case, because this pivot occurred under the specific circumstances of a legacy biotech pipeline failure and a change of controlling shareholder, governance and financial-stability uncertainties appear comparatively larger than for other bitcoin-holding companies.
In addition, because the company itself is undergoing listing-eligibility review and delisting proceedings, whether the business continues at all functions as a more fundamental variable than competitive positioning within the sector.
The most important near-term variable is the outcome of the injunction the company filed at the Seoul Southern District Court to stay the delisting decision and related procedures.
On August 20 the company sought an injunction against the Korea Exchange to suspend the effect of the delisting decision and the cleanup-trading process, and the exchange has held the delisting procedures, including cleanup trading, in abeyance pending the court's ruling.
If the injunction is denied, the exchange can reset the suspended cleanup-trading schedule and resume the process; even if it is granted, this is only a temporary measure pending a final ruling on the merits and does not guarantee continued listing.
Separately, an absorption merger with affiliate Parataxis Ethereum is also underway: the extraordinary general meeting originally set for August 4 has been pushed to November 27, the merger effective date shifted from October 1, 2026 to January 1, 2027, and the new-share listing date moved from October 23, 2026 to January 27, 2027.
The company has stated that if delisting is finalized before the merger is completed, the merger ratio could be recalculated under intrinsic-value methods or the merger terms themselves could change.
In short, over the coming months the company's form of continuation is likely to narrow to one of two paths—delisting as a standalone listed company, or survival through absorption into Parataxis Ethereum—and either path could substantially change the nature of shares currently held by shareholders.
Because the delisting process and the court's injunction review are proceeding simultaneously, conventional valuation yardsticks are difficult to apply as-is to this stock.
The level of share price relative to net assets reflects the recent restructuring of total equity through a large third-party capital raise, which should not be read as an accumulation of profit generated from operations.
Looking across multiple years, annual operating losses have trended smaller than in 2022-2023, but this cannot yet be characterized as a shift from loss to profit, and no dividend has been paid.
Rather than ordinary multiple comparisons, the progress of procedural events—whether delisting is finalized and how the affiliate merger schedule changes—functions as the more fundamental variable determining the nature of the shares and whether they can even be traded.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Through large third-party share placements in 2024-2025, equity rebuilt from a 2023 trough of roughly 19.7 billion won to about 43.8 billion won at the end of 2025. This can be read as external capital having, for now, eased the risk of capital impairment despite continuing losses.
However, it should be kept in mind that this is a change in the financial structure driven by capital raising rather than operating profit.
Unlike four consecutive quarters of zero revenue in 2025, revenue of 319 million won and 1.274 billion won was recorded in Q1 and Q2 2026 respectively. This is presumed to stem from the newly adopted business following the pivot, and can be viewed as a signal that a revenue base is beginning to form.
That said, operating losses still far exceed revenue, so this has not yet translated into an improvement in profitability.
The company has filed for a court injunction to stay the effect of the delisting decision, and separately, an absorption-merger process with affiliate Parataxis Ethereum is proceeding in parallel.
While the outcome of neither path has been finalized, it is a confirmed fact that a process keeping open the possibility of continuation beyond outright delisting is underway.
KRX's Corporate Examination Committee resolved to delist the stock on July 1, and after the company's objection was rejected, the KOSDAQ Market Committee again resolved delisting on August 19.
The process had already advanced to the cleanup-trading stage before being suspended by the court injunction filing, and could resume immediately if the injunction is denied.
The Phase 2 failure of IPF candidate BBT-877 was the direct trigger for the change in controlling shareholder, and the sharp jump in the Q4 2025 net loss attributable to owners to 19.229 billion won also suggests the influence of a related one-off factor.
The financial burden stemming from the failed drug development has not been fully resolved even after the business pivot.
In all four years from 2022 to 2025, operating losses exceeded 15 billion won and operating cash flow was negative every year. With revenue at an extremely low level, losses have kept repeating, and whether the business pivot will actually translate into improved profitability has yet to be confirmed.
Whether delisting proceeds depends on the outcome of the Seoul Southern District Court's injunction review and any subsequent ruling on the merits. If the injunction is denied, cleanup trading could resume; even if granted, delisting risk is not fully eliminated until a final ruling on the merits. The stock remains under a trading halt, so liquidity risk must also be considered.
The pre-tax loss ratio exceeded 50% of equity in both 2023 and 2024, and reached 74.8% in 2025, triggering the listing-eligibility review. With the revenue base still minimal, the repetition of large annual losses and negative operating cash flow could translate into a need for further capital raising going forward.
After control changed hands through a third-party placement affiliated with a cryptocurrency hedge fund manager, the business pivoted toward a bitcoin treasury operation unrelated to the legacy biotech business.
This sector still lacks a standardized accounting and regulatory framework, leaving ongoing uncertainty from potential policy changes or fluctuations in digital-asset values.
Watch for the Seoul Southern District Court's ruling on the injunction to stay the delisting decision and related procedures. If denied, cleanup trading and delisting could resume; even if granted, a ruling on the merits of the underlying lawsuit would still be pending.
Scheduled date of the extraordinary general meeting to approve the absorption merger with Parataxis Ethereum; the status of the delisting process could affect whether and on what terms the merger is approved.
The currently planned merger effective date; the company has disclosed that if delisting is finalized before this date, the merger ratio or terms could be recalculated.
The planned listing date for new shares issued in the merger; if the merger proceeds as planned, this is when existing shareholders' shares would convert into new Parataxis Ethereum shares.
Paratax is Korea (or the company) experienced a change in its largest shareholder following the failure of its new drug pipeline, subsequently pivoting to a bitcoin treasury business, and is now in an unusual situation where delisting procedures, a court injunction, and an affiliate merger schedule are all proceeding simultaneously.
Looking at the confirmed financials, the revenue base remains minimal, while annual operating losses have exceeded KRW 15 billion each year; meaningful revenue appeared for the first time in 2026, but it has not been enough to offset the losses.
Shareholders' equity has been rebuilt through a large-scale rights offering, which is qualitatively different in nature since it stems from external capital raising rather than operating profit.
Whether the company will be delisted depends on the outcome of the court injunction and the main lawsuit, while the form in which the business continues depends on whether the absorption-type merger with Paratax Ethereum is completed—neither of these two processes has yet reached a conclusion.
From an investor's perspective, it is necessary to prioritize monitoring the progress of these two procedural events over conventional performance and valuation metrics. This report is for informational purposes only and does not include a buy/sell recommendation or a target price.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.